Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy.

被引：0
|
作者：
Takahashi, Chiaki [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa, Japan
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1001
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CDK4/6 inhibitor resistance: A bibliometric analysis
    Pang, Jiayuecheng
    Li, Hengyu
    Sheng, Yuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Astex shapes CDK4/6 inhibitor for approval
    Peplow, Mark
    NATURE BIOTECHNOLOGY, 2017, 35 (05) : 395 - 396
  • [43] Oral CDK4/6 inhibitor in clinical trials
    Bennet, Neil
    LANCET ONCOLOGY, 2012, 13 (03): : E91 - E91
  • [44] CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
    Rubio, Carolina
    Martinez-Fernandez, Monica
    Segovia, Cristina
    Lodewijk, Iris
    Suarez-Cabrera, Cristian
    Segrelles, Carmen
    Lopez-Calderon, Fernando
    Munera-Maravilla, Ester
    Santos, Mirentxu
    Bernardini, Alejandra
    Garcia-Escudero, Ramon
    Lorz, Corina
    Jose Gomez-Rodriguez, Maria
    de Velasco, Guillermo
    Otero, Irene
    Villacampa, Felipe
    Guerrero-Ramos, Felix
    Ruiz, Sergio
    de la Rosa, Federico
    Dominguez-Rodriguez, Sara
    Real, Francisco X.
    Malats, Nuria
    Castellano, Daniel
    Duenas, Marta
    Paramio, Jesus M.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 390 - 402
  • [45] Targeting CDK4/6 for Anticancer Therapy
    Qi, Jiating
    Ouyang, Zhuqing
    BIOMEDICINES, 2022, 10 (03)
  • [46] Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer
    Shi, Xinan
    Li, Hongjian
    Shi, Anhua
    Yao, Hong
    Ke, Kunbin
    Dong, Chao
    Zhu, Ying
    Qin, Yi
    Ding, Ying
    He, Yan Hong
    Liu, Xu
    Li, Ling
    Lei, Ling
    Hai, Qingshan
    Chen, Wei
    Leung, Kwong-Sak
    Wong, Man-Hon
    Kung, Hsiang-Fu
    Lin, Marie Chia-Mi
    ONCOLOGY REPORTS, 2018, 40 (03) : 1592 - 1600
  • [47] Clarithromycin Interactions with Palbociclib (CDK4/6 Inhibitor)
    Hu, Xiuqiong
    Yang, Wei
    Liu, Lanjie
    Qin, Hua
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (07): : 1698 - 1707
  • [48] Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel
    Smith, Elizabeth R.
    Huang, Marilyn
    Schlumbrecht, Matthew P.
    George, Sophia H. L.
    Xu, Xiang-Xi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] RB loss mitigates CDK4/6 inhibitor-mediated radiosensitization of estrogen receptor positive (ER plus ) breast cancers.
    Pesch, Andrea M.
    Hirsh, Nicole
    Michmerhuizen, Anna R.
    Chandler, Benjamin C.
    Wilder-Romans, Kari
    Liu, Meilan
    Cobain, Erin
    Pierce, Lori J.
    Rae, James M.
    Speers, Corey
    CLINICAL CANCER RESEARCH, 2021, 27 (08)
  • [50] CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
    Arsenijevic, Tatjana
    Coulonval, Katia
    Raspe, Eric
    Demols, Anne
    Roger, Pierre P.
    Van Laethem, Jean-Luc
    CANCERS, 2023, 15 (03)
12345